View More View Less
  • 1 Semmelweis Egyetem, Általános Orvostudományi Kar, Budapest
  • 2 Semmelweis Egyetem, Általános Orvostudományi Kar, Budapest
  • 3 Hospital Universitario Son Espases, Palma de Mallorca, Spanyolország
  • 4 MTA-TTK Lendület Onkológiai Biomarker Munkacsoport, Budapest
Open access

Absztrakt:

A colorectalis daganatra ma már igen heterogén betegségként tekintünk, mely heterogenitást a kialakulásában szerepet játszó genetikai faktorok, molekuláris eltérések, különböző jelátviteli útvonalak, valamint mikro- és makrokörnyezeti tényezők okoznak. A korábban ismert „klasszikus” adenoma-carcinoma szekvencia mellett az elmúlt évtizedben egy másik, alternatív útvonal is felismerésre került. Ezt „fogazott” útvonalnak nevezzük, mely az elváltozások kb. egyharmadáért felelős. Ezek a laesiók a molekuláris tulajdonságaikon felül makroszkópos és mikroszkópos képükben és progressziós hajlamukban, illetve prognózisukban is eltérnek a klasszikus útvonal daganataitól. Az alábbi összefoglaló közlemény ezen eltérések molekuláris tulajdonságait, makroszkópos és szövettani jellegzetességeit, illetve klinikai jelentőségét szemlélteti. Orv Hetil. 2018; 159(6): 206–214.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • 1

    Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal-tumor development. N Engl J Med. 1988; 319: 525–532.

  • 2

    JE IJ, Medema JP, Dekker E. Colorectal neoplasia pathways: state of the art. Gastrointest Endosc Clin N Am. 2015; 25: 169–182.

  • 3

    Imamura Y, Lochhead P, Yamauchi M, et al. Analyses of clinicopathological, molecular, and prognostic associations of KRAS codon 61 and codon 146 mutations in colorectal cancer: cohort study and literature review. Mol Cancer 2014; 13: 135.

  • 4

    Hinoue T, Weisenberger DJ, Lange CP, et al. Genome-scale analysis of aberrant DNA methylation in colorectal cancer. Genome Res. 2012; 22: 271–282.

  • 5

    Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, et al. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res. 2007; 67: 2643–2648.

  • 6

    Jass JR. Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology 2007; 50: 113–130.

  • 7

    Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol. 2005; 23: 609–618 .

  • 8

    Roth AD, Tejpar S, Delorenzi M, et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol. 2010; 28: 466–474.

  • 9

    Wong IH. Methylation profiling of human cancers in blood: molecular monitoring and prognostication (review). Int J Oncol. 2001; 19: 1319–1324.

  • 10

    Hughes LA, Khalid-de Bakker CA, Smits KM, et al. The CpG island methylator phenotype in colorectal cancer: progress and problems. Biochim Biophys Acta 2012; 1825: 77–85.

  • 11

    Moussata D, Boschetti G, Chauvenet M, et al. Endoscopic and histologic characteristics of serrated lesions. World J Gastroenterol. 2015; 21: 2896–2904.

  • 12

    Cancer Genome Atlas N. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012; 487: 330–337.

  • 13

    Guinney J, Dienstmann R, Wang X, et al. The consensus molecular subtypes of colorectal cancer. Nat Med. 2015; 21: 1350–1356.

  • 14

    Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61: 759–767.

  • 15

    Zoratto F, Rossi L, Verrico M, et al. Focus on genetic and epigenetic events of colorectal cancer pathogenesis: implications for molecular diagnosis. Tumour Biol. 2014; 35: 6195–6206.

  • 16

    Bosman FT, Yan P. Molecular pathology of colon cancer. Pol J Pathol. 2014; 65(Suppl 1): S1–S11.

  • 17

    Dienstmann R, Vermeulen L, Guinney J, et al. Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer. Nat Rev Cancer 2017; 17: 79–92.

  • 18

    O’Brien MJ. Hyperplastic and serrated polyps of the colorectum. Gastroenterol Clin North Am. 2007; 36: 947–968.

  • 19

    Bae JM, Kim JH, Kang GH. molecular subtypes of colorectal cancer and their clinicopathologic features, with an emphasis on the serrated neoplasia pathway. Arch Pathol Lab Med. 2016; 140: 406–412.

  • 20

    Bosman FT, World Health Organization, International Agency for Research on Cancer. WHO classification of tumours of the digestive system. 4th edn. International Agency for Research on Cancer, Lyon, 2010.

  • 21

    Bettington M, Walker N, Clouston A, et al. The serrated pathway to colorectal carcinoma: current concepts and challenges. Histopathology 2013; 62: 367–386.

  • 22

    Rex DK, Ahnen DJ, Baron JA, et al. Serrated lesions of the colorectum: review and recommendations from an expert panel. Am J Gastroenterol. 2012; 107: 1315–1329.

  • 23

    Rex DK, Ulbright TM. Step section histology of proximal colon polyps that appear hyperplastic by endoscopy. Am J Gastroenterol. 2002; 97: 1530–1534.

  • 24

    Jass JR. Hyperplastic polyps of the colorectum – innocent or guilty? Dis Colon Rectum 2001; 44: 163–166.

  • 25

    Langner C. Serrated and non-serrated precursor lesions of colorectal cancer. Dig Dis. 2015; 33: 28–37.

  • 26

    Bettington M, Walker N, Rosty C, et al. Critical appraisal of the diagnosis of the sessile serrated adenoma. Am J Surg Pathol. 2014; 38: 158–166.

  • 27

    Singh R, Zorrón Cheng Tao Pu L, Koay D, et al. Sessile serrated adenoma/polyps: Where are we at in 2016? World J Gastroenterol. 2016; 22: 7754–7759.

  • 28

    IJspeert JE, Bastiaansen BA, van Leerdam ME, et al. Development and validation of the WASP classification system for optical diagnosis of adenomas, hyperplastic polyps and sessile serrated adenomas/polyps. Gut 2016; 65: 963–970.

  • 29

    Bateman AC. Pathology of serrated colorectal lesions. J Clin Pathol. 2014; 67: 865–874.

  • 30

    Bettington ML, Chetty R. Traditional serrated adenoma: an update. Hum Pathol. 2015; 46: 933–938.

  • 31

    Chetty R. Traditional serrated adenoma (TSA): morphological questions, queries and quandaries. J Clin Pathol. 2016; 69: 6–11.

  • 32

    Bettington ML, Walker NI, Rosty C, et al. A clinicopathological and molecular analysis of 200 traditional serrated adenomas. Mod Pathol. 2015; 28: 414–427.

  • 33

    Yamane L, Scapulatempo-Neto C, Reis RM, et al. Serrated pathway in colorectal carcinogenesis. World J Gastroenterol. 2014; 20: 2634–2640.

  • 34

    Rhee YY, Kim KJ, Kang GH. CpG island methylator phenotype-high colorectal cancers and their prognostic implications and relationships with the serrated neoplasia pathway. Gut Liver 2017; 11: 38–46.

  • 35

    Samadder NJ, Vierkant RA, Tillmans LS, et al. Associations between colorectal cancer molecular markers and pathways with clinicopathologic features in older women. Gastroenterology 2013; 145: 348–356.

  • 36

    Tosolini M, Kirilovsky A, Mlecnik B, et al. Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, Th2, Treg, Th17) in patients with colorectal cancer. Cancer Res. 2011; 71: 1263–1271.

  • 37

    Phipps AI, Limburg PJ, Baron JA, et al. Association between molecular subtypes of colorectal cancer and patient survival. Gastroenterology 2015; 148: 77–87.e2.

  • 38

    Juo YY, Johnston FM, Zhang DY, et al. Prognostic value of CpG island methylator phenotype among colorectal cancer patients: a systematic review and meta-analysis. Ann Oncol. 2014; 25: 2314–2327.

  • 39

    Russo A, Bazan V, Agnese V, et al. Prognostic and predictive factors in colorectal cancer: Kirsten Ras in CRC (RASCAL) and TP53CRC collaborative studies. Ann Oncol. 2005; 16(Suppl 4): iv44–iv49.

  • 40

    Kaminski MF, Regula J, Kraszewska E, et al. Quality indicators for colonoscopy and the risk of interval cancer. N Engl J Med. 2010; 362: 1795–1803.

  • 41

    Pohl H, Srivastava A, Bensen SP, et al. Incomplete polyp resection during colonoscopy – results of the complete adenoma resection (CARE) study. Gastroenterology 2013; 144: 74–80.

  • 42

    Pohl H, Robertson DJ. Colorectal cancers detected after colonoscopy frequently result from missed lesions. Clin Gastroenterol Hepatol. 2010; 8: 858–864.

  • 43

    Vecchione L, Jacobs B, Normanno N, et al. EGFR-targeted therapy. Exp Cell Res. 2011; 317: 2765–2771.

  • 44

    Burt RW. Diagnosing Lynch syndrome: more light at the end of the tunnel. Cancer Prev Res. (Phila.) 2012; 5: 507–510.

  • 45

    Graham DM, Coyle VM, Kennedy RD, et al. Molecular subtypes and personalized therapy in metastatic colorectal cancer. Curr Colorectal Cancer Rep. 2016; 12: 141–150.

  • 46

    Sargent DJ, Marsoni S, Monges G, et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol. 2010; 28: 3219–3226.

  • 47

    Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015; 372: 2509–2520.

  • 48

    Schlicker A, Beran G, Chresta CM, et al. Subtypes of primary colorectal tumors correlate with response to targeted treatment in colorectal cell lines. BMC Med Genomics 2012; 5: 66.

  • 49

    Bordaçahar B, Barret M, Terris B, et al. Sessile serrated adenoma: from identification to resection. Dig Liver Dis. 2015; 47: 95–102.

  • 50

    Lieberman DA, Rex DK, Winawer SJ, et al. Guidelines for colonoscopy surveillance after screening and polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology 2012; 143: 844–857.

  • 51

    Carethers JM, Murali B, Yang B, et al. Influence of race on microsatellite instability and CD8+ T cell infiltration in colon cancer. PLoS ONE 2014; 9: e100461.

  • 52

    Müller MF, Ibrahim AE, Arends MJ. Molecular pathological classification of colorectal cancer. Virchows Arch. 2016; 469: 125–134.